🔒 This section is part of the full guide
You're browsing the free preview. This section is part of the complete Mold Treatment Playbook — the full treatment protocols, S/CS dosing card, lab interpretation, and clinician tools.
Unlock everything — full treatment protocols, dosing card, lab interpretation, and every clinician tool.
Yearly — → Own it forever — →Free in the preview: Quick Start one-pager · tool demos (marker lookup, fold calculator, symptom questionnaire) · the Evidence & key literature library · Faculty & sources. Everything else unlocks with your code.
Quick start — the whole protocol at a glance
If you read nothing else, read this. The one-screen version — what to order, the order of operations, and where to send it. Every line links to the full detail. Need doses fast? → ℞ Rx quick card (S/CS). The rule that governs all of it: low and slow — a flare is "too much, too soon," not failure.
The treatment arc — order of operations
| # | Step | The move in one line |
|---|---|---|
| 0 | Confirm & remove exposure | You cannot heal in it. Building test + urine mycotoxins to prove it; remediate or leave. |
| 1 | Prepare the terrain (if sensitive) | Limbic + vagal first; ≥6 wk in the very sensitive, then add mast-cell. Reduce inflammation: H1 + H2, quercetin/DAO/Perimine/PEA → cromolyn/ketotifen. |
| 2 | Bind & drain | Open the drains first (bowels, water, bile, sweat). Match the binder to the toxin; start at a fraction of a dose. |
| 3 | Clear colonization | Sinus + gut antifungals by tolerance; biofilm agents; "race to the antifungals" when gliotoxin is high. |
| 4 | Recover | Immune reboot (LDN, VIP, peptides), hormones, mitochondria last. Ketamine/LDI for the truly untreatable. |
| 5 | Re-test & re-sequence | Re-check urine mycotoxins + cytokines at ~3–4 months; numbers often rise before they fall as detox improves. Stuck? → decision tree. |
What to order — the lab sheet
| Tier | Order |
|---|---|
| Initial every complex patient | Building test (plates/ERMI) + urine mycotoxins; CBC w/ diff, CMP, ferritin, hs-CRP; iron studies (Fe/TIBC/%sat); full thyroid (TSH, fT3, fT4, rT3, TPO+Tg ab); fasting glucose + insulin; DHEA-S + timed cortisol; vitamin D 25-OH; Ig G/A/M/E. |
| Consider by picture | OAT/GPL-OAT (GI/gliotoxin); ApoB/ApoA1 + NMR; homocysteine, B12/folate, RBC-Mg, zinc/copper/ceruloplasmin; Cystatin C + hypercoagulation genetics; cytokine panel (stuck patient); Cyrex Array 2/LBP; environmental toxicants + glyphosate. |
| Specialty targeted | Co-infections — IGeneX Lyme-IgG + Bartonella-IgG immunoblots + Bartonella FISH (+ Babesia by symptoms); T-Labs (active); ELISpot; CD57/NK — read by ILADS. Actino/nasal NGS (MicroGenDx); CIRS biomarkers (supportive); genomics (IntellxxDNA); TH1/TH2/TH17. |
Where to send it — sourcing map (links open the lab's site — sign in with your practitioner account)
| What | Where to order |
|---|---|
| Routine chem / CBC / thyroid / iron / hormones / hs-CRP | LabCorp / Quest — direct or via Rupa / Fullscript |
| Urine mycotoxins | RealTime (RTL) — Nathan's gold standard for follow-up/monitoring. Add Mosaic (MycoTOX) when you want mycophenolic acid (acute-exposure marker RTL doesn't measure). A positive from any lab makes the dx; don't cross-compare methods — pick one and trend on it. Challenge: glutathione 500 mg BID ×7 d, collect day 7; off binders 3 d for repeats. |
| OAT (organic acids) | Mosaic / GPL-OAT — via Rupa/Fullscript |
| Building test — ERMI / HERTSMI-2 | EnviroBiomics, Mycometrics (dust); plates → local; see the two-step explainer |
| Actinomycetes / nasal & sinus | EnviroBiomics (#13/#21/#29); MicroGenDx NGS |
| Co-infections (Lyme/Bartonella/Babesia) | IGeneX (immunoblots + FISH) & T-Lab (active); ELISpot via ArminLabs |
| Cytokine panel | IncellDx / Radiance (direct); CytoDx via Rupa/Fullscript; Mayo/ARUP "13" (send-out) |
| Environmental toxicants / glyphosate | RealTime, Mosaic — Rupa/Fullscript |
| Genomics | IntellxxDNA (practitioner account) |
The core initial labs — the "why" and the ratio that matters
| Lab | Why you order it | Read alongside / ratio |
|---|---|---|
| CBC w/ differential | Baseline marrow/immune picture. Eosinophils & basophils up = an MCAS/allergy/parasite clue. | NLR (neutrophil:lymphocyte, <2) systemic inflammation; PLR (<100) prothrombotic/immune; MEB (mono+eos+baso) gut-barrier leak |
| CMP | Liver, kidney, electrolytes, protein — organ capacity to detox and clear. | A/G ratio (>1.4) — low = chronic antigen load (Lyme/mold/autoimmune); BUN/creat & eGFR beside Cystatin C |
| Ferritin | Iron stores — and an acute-phase reactant, so it rises with inflammation. | Never read alone — use the iron quadrant (Fe + TIBC + %sat + ferritin) so you don't iron-load an inflamed patient |
| hs-CRP | Systemic inflammatory load and a treatment-response marker. | Read copper/ceruloplasmin beside it (both acute-phase) — a "high copper" here is usually inflammation, not overload |
Full functional-optimal targets and every ratio are in Lab Interpretation; drop your values into the Functional Lab Interpreter to compute them automatically, or look up any single marker in the Marker Lookup.
How to use this guide
This is my working clinical guide for evaluating and treating complex mold- and mycotoxin-driven illness — the patients who arrive already labeled, already treated, and still not well. It is organized the way I actually work a patient up: we start at testing, then move through the treatment sequence in the order the body will tolerate it.
New to treating mold? Read this first start here
Mold and mycotoxin illness is a newer area for most of us — very little of it shows up in standard training, whatever your background, and it wasn't in mine either. That's normal. It's a different way of thinking, and once these shifts click, the protocols make sense instead of feeling like a random list of supplements. The big ones:
- You're treating a terrain, not a diagnosis. Sequence and readiness matter more than which agent you pick — the same right treatment helps or harms depending on when you give it.
- "Low and slow" is a safety rule, not timidity. More is not better here — an over-dose mobilizes toxin faster than the patient can clear it and can set them back for weeks. Starting at a fraction of a dose is the skilled move, not the cautious one.
- Normal labs do not mean well. These patients are often sick inside "normal" conventional ranges — you read against functional-optimal targets and the ratios, not just the flag (see Lab Interpretation).
- A flare is information, not failure. When a patient reacts, it usually tells you about terrain or sequence (too much, too soon, skipped the mast-cell/limbic prep) — not that the drug "didn't work."
- Understand the why, don't memorize the dose. The mechanism is what lets you adapt when a patient doesn't fit the protocol — like knowing molybdenum clears the sulfite bottleneck, so you can support a sulfur-reactive patient instead of just stopping. Every dose in here comes with its rationale for exactly that reason.
- It's multi-system and multi-driver. Mold rarely travels alone (Lyme, MCAS, viral reactivation, PANS) — you treat the driver that explains the most, usually mold, and watch the rest settle.
So don't try to memorize this guide. Read the "why" boxes — they're here so you can reason at the bedside, which is what treating these patients actually requires. It was a steep curve for me years ago too; the depth is the point.
The one idea that governs everything: sequence
These patients do not fail treatment because we picked the wrong binder. They fail because we gave the right thing in the wrong order. A body that does not feel safe cannot heal — so in a sensitive patient we prepare the terrain (limbic, vagal, mast cell) before we push binders or detox, or we throw them under the bus. You'll see that logic embedded at each decision point rather than lectured up front.
Three mental models run quietly underneath the whole guide — you'll meet them where they matter, not as theory:
- Cell Danger Response — the cell that senses ongoing threat downshifts healing, detox, and repair. This is why safety work comes first.
- The biotoxin pathway — the inflammatory cascade that explains the multi-system symptom picture.
- The three-mechanism model — mold acts through allergy, infection, and toxicity; we're focused on toxicity, but all three can coexist.
The reframe that keeps you sane
The goal is not to remove every molecule of toxin. It is to remove enough that the immune system reboots itself and takes over the job. Most systems that stalled — methylation, mitochondria, hormones, immunity — come back online on their own once the toxin load drops below the patient's threshold.
Mold makes everything else worse. It potentiates Lyme and co-infections, reactivates viruses, drives mast cell activation, and sits under many PANS/PANDAS pictures. In any stalled complex patient, it belongs on the list.
Navigation: use the left menu for the clinical workflow (Testing → Recovery), the Quick Guides for point-of-care cards, and Tools for the calculators. Global search is top-right.
Testing & diagnosis
The workup runs in this order: decide who to test → test the building → test the patient (urine mycotoxins) → read the results by ratio, not just against optimal ranges → layer in adjunct labs only where they earn their place.
1 · When to suspect — who to test
Screen for mold in any multi-system, treatment-refractory patient, and reflexively when you hear the keynotes — the symptoms that should make you think mold before anything else:
Keynote "think-mold" symptoms
- Ice-pick / lightning-bolt pains; non-dermatomal paresthesias (center of head, chest, back)
- An internal vibration or tremor the patient feels but you can't see
- Escalating sensitivity to everything — light, sound, touch, smell, food, chemicals, EMF
- New-onset or wildly out-of-control anxiety, panic, depersonalization/derealization, OCD
- Word-finding trouble, recent-memory loss, "I feel inept"
Mold masquerades as CFS/fibromyalgia, "atypical" MS, early Parkinson's/Alzheimer's language, autoimmune disease, and new-onset psychiatric illness. The unifying history is an immune hit that unmasked it — COVID, flu, surgery, childbirth, menopause, or emotional upheaval — after which a person who had tolerated their environment suddenly couldn't.
Start the visit with a structured symptom screen (see the Symptom Burden Screener in Tools). A high, wide-ranging score also does something clinical: it gives the patient the confidence to follow through on testing and treatment.
2 · Test the building — early, before you chase the patient
Check the home and work environment at the start. Nothing downstream works while exposure continues, and you don't want to discover the moldy house a year in.
| Method | Where to get it | How to read it |
|---|---|---|
| Mold plates (settle/gravity) | Immunolytics — DIY petri dishes mailed back for analysis (also runs an IEP referral network) | Open dish on the floor 1 hr, cap, label by room, wait 4–5 days. Colonies → mail back and flag that room. |
| ERMI / HERTSMI-2 dust DNA (MSQPCR) | Mycometrics (ERMI ~$285 / HERTSMI ~$150; AccuDust vacuum or AccuCloth Swiffer collection) · EnviroBiomics · EMLab P&K (Eurofins) | HERTSMI-2: <11 safe · 11–15 borderline (remediate + re-test) · >15 unsafe for an ill patient. Weigh which of the "Big 5" are present — A. penicillioides, A. versicolor, Chaetomium globosum, Stachybotrys chartarum, Wallemia sebi. |
| Air sampling | Industry standard | Least accurate for our purposes — spores are heavy and sit on the floor, not mid-room. A clean air sample does not clear a room. |
| On-site inspection | A certified Indoor Environmental Professional (IEP) — find one via the ISEAI IEP list or ACAC (CIEC / CIE credentials) | Assesses moisture, HVAC, and building science. Use an IEP who is not the remediation contractor — avoid the conflict of interest. |
Plates vs. ERMI/HERTSMI-2 — what each test actually does (and why they aren't the same test)
The confusion around "why two tests" disappears once you see that they answer two different questions. One tells you where the mold is; the other tells you how bad it is and whether the home is clean after remediation. They are complements, not duplicates.
| Mold plates (settle / gravity) | ERMI / HERTSMI-2 (dust DNA, MSqPCR) | |
|---|---|---|
| The question it answers | "Is something actively growing — and which room?" | "How contaminated is this space, and is it safe after remediation?" |
| How it works | An open dish collects viable, currently-airborne spores that settle and then grow into countable colonies. You set one in every room. | qPCR reads the DNA of 36 water-damage species in settled dust — alive or dead — and returns a quantitative, scored result (HERTSMI-2: <11 safe · 11–15 borderline · >15 unsafe for an ill patient). |
| Its unique strength | Localization. Cheap and DIY, so you can screen room-by-room and find the source. When every room shows heavy growth of one toxic species (e.g. Penicillium), that pattern points you at the HVAC system. | Grading & clearance. Accurate enough to judge severity, guide remediation, and — the part plates can't do — confirm the home is clean afterward with a re-test. |
| Where it falls short | Crude. Not accurate enough to grade severity or to clear a home through remediation. A negative usually means safe — but not always; if the patient isn't responding to treatment, test further. | Usually a composite of several rooms, so a positive tells you the house has a problem but not which room is the culprit. |
So match the test to the decision: localize the source with plates; grade the space and prove it's clean after remediation with ERMI/HERTSMI-2. You only need both when you need both jobs done — and if exposure is already obvious and the patient clearly improves away from the building, you may not need environmental testing to prove a diagnosis you've already made.
3 · Test the patient — urine mycotoxins
Urine mycotoxin testing is the most direct confirmation: toxin in the urine means toxin in the body. Know what each lab measures — and how to call a positive — right here, so you don't have to jump elsewhere at the point of care.
| Lab / method | What it measures | What counts as positive / how to interpret |
|---|---|---|
| RealTime Labs (ELISA; now US Biotech) | Indirect — tags toxins and metabolites; 5 families / 16 measurements. Not creatinine-controlled. | Any value above the lab's reference cutoff is meaningful. Preferred for follow-up — most reliable for tracking a trend over time. |
| Mosaic / Vibrant (LC-MS/MS) | Direct molecular ID; creatinine-controlled; adds mycophenolic acid (a current-exposure clue). | Positive = specific toxin identified above cutoff. Creatinine-corrected, so less fooled by dilution. May miss metabolites it isn't set to watch. |
| MyMyco (Campbell; blood antibody) | IgE / IgG antibodies to mycotoxins & fungal elements. | A positive makes the diagnosis. IgE positivity suggests a more acute exposure — useful when you need to know "is this current?" |
Which test, when
- Poor detoxifier (clearly sick but likely can't excrete): lead with MyMycoLab serum antibodies — no wash-out or provocation needed.
- Kidney disease / dilution concerns: prefer a creatinine-corrected LC-MS/MS (Mosaic / Vibrant); RTL is not creatinine-corrected.
- "Is it active right now?": LC-MS/MS mycophenolic acid, or MyMyco IgE (exposure in the past 2–4 weeks).
- Provocation caveat: glutathione provocation can skew LC-MS/MS results — follow each lab's prep exactly.
A strong first run: a urine mycotoxin test and a serum antibody test the same day, alongside the symptom questionnaire — three angles on one picture.
MyMycoLab (Campbell) — the blood antibody test, in detail
Unlike the urine tests (which measure excreted toxin), MyMycoLab is a serum antibody test — it measures the body's IgG and IgE antibodies to mycotoxins, i.e. the immune response, not the toxin itself (conceptually like antibody testing for an infection). It's a 14-mycotoxin panel (expanded from 12 — added Fumonisin B1 and zearalenone — alongside the aflatoxins, ochratoxin, trichothecenes, gliotoxin, and others).
- IgG positive → suggests current/ongoing exposure and/or fungal colonization — the immune system has "seen" the mycotoxin.
- IgE positive → suggests current exposure with mast-cell / allergic activation — the "is this active right now?" signal; source may be home, work, school, or an intermittent venue.
When an attorney or court is involved — test for what will hold up
Testing strategy changes in litigation. Urine mycotoxin testing is contested and frequently dismissed by opposing experts — criticized for lacking validated control ranges, being unable to separate dietary from inhaled exposure, and not tying a level to a specific disease. Even the Shoemaker methodology (the re-exposure biomarker protocol, C4a / TGF-β1 / MMP-9 / VEGF / MSH, and VCS) has been excluded in court — a Maryland Frye-Reed ruling found it lacked "general acceptance" and didn't account for exposure dose (a Daubert jurisdiction might rule differently).
So for legal cases, anchor to the most defensible evidence: certified environmental testing with a documented chain of custody by a credentialed IEP (ACAC / ISEAI) plus objective water-damage / moisture documentation; add blood antibody testing (MyMycoLab) as a body-side data point; and recognize that Shoemaker's re-exposure protocol and NeuroQuant volumetric MRI — while persuasive to CIRS-literate courts — are attackable where "general acceptance" is the bar. General information, not legal advice — coordinate the testing plan with the patient's attorney and the applicable Frye/Daubert standard.
Collection & provocation protocol
- First-morning, concentrated urine. A dilute specimen (over-hydrated) reads falsely low — this is the creatinine caveat for uncontrolled assays.
- Provoke for a truer result: glutathione 500 mg BID × 7 days, collect on day 7. For glutathione-intolerant patients, use mixed bioflavonoids (e.g., quercetin 500 mg BID × 7 days) instead. A sauna / hot bath ~1 hour before collection improves yield.
- Repeat tests: stop all binders 3–4 days prior.
Safety — don't out-run the patient
Provocation does what it's supposed to: it mobilizes toxin. If a sensitive patient starts getting worse on the glutathione challenge, collect the urine then and stop — the provocation is already done. Do not keep mobilizing toxin faster than they can clear it.
4 · Reading the results — the comparing & ratio method signature
Read every value two ways. First against the functional-optimal range — that tells you the direction and where the target sits. Then compute the fold-elevation and read it as a ratio — that tells you the magnitude the optimal range alone hides.
The factorial ("fold above normal") read
Take the result and divide it by the lab's reference cutoff. That's how many times above normal the patient is. A result of 4.44 sitting next to a 0.5 cutoff looks "a little high" to a patient — until you show them it's nearly 9× above what a healthy body should carry. Do this for every marker.
Why the ratio earns its place alongside the optimal range: it captures magnitude, it lets you rank markers against each other (gliotoxin 9× vs. trichothecene 2× tells you where to aim first), and it lets you track the fold-change over time as a real measure of progress. Use the Fold-Elevation Calculator to do it in seconds and show the patient.
Reading ratios and indices on co-infection panels: the same logic applies to antibody indices — read the index against its ratio threshold, not just positive/negative. As a working red-flag line, an index climbing above ~0.700 earns attention even when the lab calls it equivocal. Low natural-killer-cell function can corroborate a clinically obvious but serologically "negative" co-infection.
"Tip of the iceberg" — a low first result is not reassurance
In a clearly sick patient, a low first panel usually means compromised detoxification, not low body burden — they can't move toxin into urine yet. Tell the patient up front: about 80% of the time the second test runs higher as detox improves, and that is good news, not failure.
Interpreting rising numbers on a repeat
| Clinical picture | Numbers went up means… |
|---|---|
| Patient feels better | Improved detoxification — expected, encouraging. Stay the course. |
| Patient not better | Re-exposure, ongoing exposure, too much binder/antifungal, or treatment-stimulated toxin production. Re-check the environment and the doses. |
Always read the number in clinical context and as a ratio to the prior result — the trend is the signal, not any single value. Repeat every 3–4 months; it does not change week to week.
5 · The baseline workup — labs I run on the complex patient
Beyond the mold panel, the complex patient needs a foundational workup — mold rarely travels alone, and the systems it disrupts (thyroid, adrenal, immune, kidney, coagulation) need eyes on them from the start.
Lab ordering at a glance — Initial · Consider · Specialty
Match the panel to the visit. Everything here is interpreted against functional-optimal targets and functional ratios — see the Lab Interpretation Reference and run the numbers in the Functional Lab Interpreter.
| Tier | Order |
|---|---|
| Initial every complex patient | Building test (plates/ERMI) + urine mycotoxins; CBC w/ differential, CMP, ferritin, hs-CRP; full iron studies (Fe, TIBC, % sat); full thyroid (TSH, Free T3, Free T4, reverse T3, TPO + Tg abs); fasting glucose + fasting insulin; DHEA-S + timed (saliva) cortisol; vitamin D (25-OH); immunoglobulins IgG/IgA/IgM/IgE. |
| Consider adding by the clinical picture | OAT / GPL-OAT (GI symptoms or gliotoxin — gut fungal markers); ApoB, ApoA1 + NMR particles (LDL-P, small LDL-P, large HDL-P) for cardiometabolic risk; homocysteine, B12/folate, RBC magnesium, zinc/copper/ceruloplasmin (methylation + mineral balance); Cystatin C + hypercoagulation-genetics panel (the ~20% who over-produce fibrin); cytokine panel (the stuck patient — see below); Cyrex Array 2 / LBP (endotoxin/leaky gut); environmental-toxicant panel + glyphosate. |
| Specialty targeted / referral | Co-infections — IGeneX immunoblots + IGeneX/T-Labs PCR-FISH (what's present now), ELISpot, CD57/NK function — read by ILADS, not CDC (criteria below); Actinomycetes / MicroGenDx nasal NGS; Shoemaker CIRS biomarkers (C4a, TGF-β1, MMP-9, VEGF, MSH — supportive only, not mold-specific); genomics (IntellxxDNA — the stuck patient); Yanuck TH1/TH2/TH17 immune panel. |
| System | What to order |
|---|---|
| Count / chemistry | CBC with differential (watch eosinophils & basophils — an MCAS clue), CMP, ferritin, hs-CRP. |
| Thyroid | TSH, Free T3, Free T4, Reverse T3 (RT3 >15 blocks T4→T3), TPO & thyroglobulin antibodies. Basal temps <97°F point to a Wilson's-type low-T3 picture. |
| Adrenal / glucose | Timed saliva cortisol (catches the midday crash a single morning serum misses), DHEA-S. Fasting glucose — symptomatic hypoglycemia often shows below 80. |
| Immune | Immunoglobulins IgG, IgA, IgM, IgE (+ subclasses); cytokine panel (sCD40L, RANTES) when teasing apart mold vs. Lyme vs. COVID. |
| Kidney / coagulation | Cystatin C (early kidney impact creatinine misses), Lp(a), fibrinogen, and the hypercoagulation-genetics panel in the ~20% who over-produce fibrin (see Biofilm). |
| Co-infections | IGeneX immunoblots (Lyme IgG, Bartonella IgG + Bartonella FISH; add Babesia with air hunger / night sweats / frontal-pressure headache); T-Labs (fresh-blood PCR-FISH — shows what's present now); ELISpot. These are immune tests — for Lyme, IgM can persist and IgG stays positive for years, so they show what the immune system "sees," not proof of current infection. |
| Environmental toxins | Mosaic / RealTime environmental-toxicant panel (15–25 chemicals); glyphosate (RealTime) — treatable, and often high even in organic eaters. |
Catching gut mold / Candida on an OAT
A urine organic-acids test (OAT / GPL-OAT) flags gut fungal overgrowth the mycotoxin panel won't: arabinose & arabitol (Candida/yeast), 5-hydroxymethyl-2-furoic & furan-2,5-dicarboxylic acids and oxalic acid (Aspergillus), tricarballylic (Fusarium), citramalic / tartaric (yeast). It also carries three terrain markers worth reading alongside: pyroglutamic acid (high = heavy glutathione utilization/depletion — the detox system is working hard), and lactic + succinic acid (mitochondrial stress — mycotoxins inhibit mitochondrial translation). Elevations point to the need for antifungal therapy — in the source series, nystatin dropped these markers 56–63%. Add the OAT when GI symptoms or gliotoxin are prominent. (Pratt-Hyatt & Shaw, Townsend Letter 2019, GPL.)
Reading Lyme serology — CDC surveillance vs ILADS clinical criteria
This is the question that trips everyone up, so let's be exact. Standard testing is two-tier: a sensitive ELISA/EIA (or C6 peptide) first, and only if that's positive/equivocal does the lab run the Western blot (immunoblot). A modified two-tier (EIA → second EIA) is now also CDC-accepted. The split is in how you read the blot.
| CDC (surveillance) — "positive" | ILADS / IGeneX (clinical) — what we count | |
|---|---|---|
| IgM | 2 of 3 bands: 23 (OspC), 39, 41. Only valid in the first ~30 days — after 1 month, IgM alone should not be used. | Treats Lyme as a clinical diagnosis. Counts the species-specific bands CDC leaves out — especially 31 (OspA) and 34 (OspB) — plus 23–25 (OspC), 39, and 83–93; reports on fewer bands, flags equivocal/IND, and uses multi-strain/species immunoblots. A patient can be ILADS-positive / clinically Lyme while CDC-negative. |
| IgG | 5 of 10 bands: 18, 23, 28, 30, 39, 41, 45, 58, 66, 93. |
Why the gap matters: the CDC criteria were built for epidemiological surveillance — tuned for specificity, not for finding every sick patient — and they deliberately drop bands 31 and 34, two of the most Borrelia-specific antigens (excluded partly to avoid confusion with the old OspA "LYMErix" vaccine, and because they show up later in infection). Those are exactly the bands a functional-medicine read wants to see.
Which bands cross-react — and which actually count: not every band carries the same weight. The 41 kDa (flagellin) is the most commonly positive band but the least specific — it's shared by all spirochetes and many flagellated bacteria (and can show up in periodontal disease, syphilis, H. pylori, even some autoimmune sera), so a lone 41 means little. The 60 / 66 / 73 kDa heat-shock proteins are similarly broad cross-reactors, and 45 / 58 are only moderately specific. What genuinely points to Borrelia are the species-specific outer-surface proteins: 23–25 (OspC), 31 (OspA), 34 (OspB), 37, 39 (BmpA), and 83–93 — a reaction on those is worth far more than a stack of nonspecific bands. This is why IGeneX uses species-specific epitopes (e.g., its 31-kDa epitope confirmation) and multi-species strips to cut the cross-reactivity a standard CDC-style blot carries.
The rule that outranks all of this: these are antibody tests — they show the immune response, not active infection. A negative two-tier does not rule out Lyme (sensitivity is low early, and in seronegative or immunosuppressed patients), and IgG can persist for years, so a positive isn't proof of current infection. Diagnose clinically; use serology alongside fresh-blood PCR/FISH (T-Labs), ELISpot, and low CD57/NK as corroboration. (CDC two-tier guidance; ILADS clinical guidelines; comparative immunoblot-criteria literature.)
What to actually order — Nathan's IGeneX shortcut order sheet
LabCorp/Quest Lyme testing is "notoriously inaccurate" (Nathan) — the front-end antibody test is "as accurate as flipping a coin," and the standard Western blot reads only B. burgdorferi, missing the 30+ Borrelia species (including the tick-borne relapsing-fever group). IGeneX has specialized in this for years; its immunoblots are especially useful for Lyme and Bartonella. The full IGeneX co-infection panel (adding Babesia, Ehrlichia, Anaplasma, Rickettsia) runs ~$2,500 — so hone in instead:
- IGeneX Lyme IgG ImmunoBlot
- IGeneX Bartonella IgG ImmunoBlot
- IGeneX Bartonella FISH
- Add Babesia when you hear the triad air hunger + night sweats + frontal-pressure headache (classic Babesia).
- To confirm something is active right now: T-Labs (Bob Mozayani, MD) — fresh-blood fluorescent PCR/FISH; you can watch the organism "light up" under the scope.
Order IgG, not IgM here, and know why: in Lyme the usual IgM→IgG sequence breaks down — IgM can predominate for years (the immune system can't class-switch), so IgM doesn't mean "acute," and IgG stays positive long after the infection is controlled (immune memory). These immunoblots tell you what the immune system has seen, not what's live today — pair with T-Labs/ELISpot for that.
6 · Adjunct labs — what I keep and what I set aside
| Test | Verdict |
|---|---|
| TGF-β1, C4a, MMP9, VEGF, MSH | Real inflammatory markers, but not specific to mold (any inflammation moves them). Note LabCorp's TGF-β1 "normal" was inflated to 20,000 by complaint, not biology — the meaningful cutoff is still ~2380. Use as supportive, not diagnostic. |
| Visual Contrast Sensitivity (VCS) | Cheap, non-invasive, supportive — but positive in Lyme and mercury too, and it normalizes long before toxin clears. Not an endpoint. |
| HLA-DR genotype | Set aside. No reliable correlation with outcome, and telling a patient they carry a "dreaded" gene can itself block healing. Don't gaslight — and don't doom. |
| MARCoNS | Largely a colonizer, not a driver. Rarely changes symptoms outside some sinus cases. |
| Cytokine panel (Radiance/IncellDx) | Promising for teasing apart mold vs. Lyme vs. COVID — sCD40L and RANTES run consistently elevated in mold. |
| Cystatin C + hypercoagulation screen | Cystatin C catches early kidney impact that creatinine misses (independent of muscle mass/diet/age). Screen the ~20% with hypercoagulation genetics — they build tougher biofilms (see Colonization & Biofilm). |
7 · Actinomycetes & endotoxins
A water-damaged building is not just mold — it's an inflammatory soup that also includes Gram-positive Actinomycetes (which off-gas antibiotic-like metabolites) and Gram-negative endotoxins/LPS (bacterial "body parts"). Suspect them in the patient with persistent microbiome imbalance, skin/sinus involvement, or MCAS that won't settle despite good mold treatment.
| Target | Building test (dust) | Body test |
|---|---|---|
| Actinomycetes | EnviroBiomics #13 (qPCR, quantitative) | EnviroBiomics Actino-Skin #21 (behind-ear / skin swab) / Nasopharynx #29; MicroGenDx nasal/sinus NGS + qPCR for species ID. Pair with the endotoxin test if sewage intrusion. |
| Endotoxins (LPS) | EnviroBiomics #5 (LAL assay) — ≤100 if CIRS; ≤200 if not | Cyrex Array 2 (serum anti-LPS IgA/IgM/IgG + leaky-gut markers); serum LBP (LPS-binding protein), sCD14, EndoCAb; immunoglobulin panel. |
Ordering: mold/mycotoxin and endotoxin body panels (RealTime, Mosaic, Vibrant, Cyrex, US BioTek) are available through practitioner platforms like Rupa Health / Fullscript; EnviroBiomics and MicroGenDx are usually ordered direct. Treatment for actinos & endotoxins is in Colonization & Antifungals.
Full mycotoxin-by-mycotoxin detail (source mold, target organs, symptom signature, and matched binder) is in the Mycotoxin Library and the Mycotoxin → Binder lookup.
Prepare the terrain — limbic, vagal & mast cell
Why this comes before binders in a sensitive patient
In the sensitized patient the nervous and immune systems are in a defensive state (the Cell Danger Response) — and a body locked in defense can't detoxify or repair. Push binders into that state and they crash. So we quiet the system first. Roughly 80% of complex mold patients have limbic/vagal involvement and ~70% have mast cell activation, so this is the rule, not the exception.
The trifecta of sensitivity
Limbic + vagal + MCAS are treated as a package — quieting only one leaves the patient hypervigilant. Map symptoms at intake:
| If you hear… | Think |
|---|---|
| Any sensitivity (light, sound, touch, smell, food, chemicals, meds, EMF); new anxiety/panic/OCD, derealization | Limbic |
| Palpitations/POTS, temperature dysregulation, insomnia; constipation, bloating, reflux, swallowing trouble, air hunger | Vagal (autonomic) |
| Reactions within 10–15 min of eating; flushing, dermatographism, hives, unpredictable food reactions | MCAS |
Sequencing rules
- Spend the first half of the first visit on limbic/vagal/MCAS — establish it's mandatory, before mold is even mentioned.
- Very sensitive: limbic + vagal alone first; get ≥6 weeks of that work before adding mast-cell treatment; then begin mold treatment.
- Less sensitive: MCAS can run concurrently with limbic/vagal — that often works better.
- Continue this work throughout treatment until the mold is gone, or it keeps re-triggering.
The third leg is reducing inflammation — calming the mast cells
Limbic and vagal work quiet the nervous system; the mast-cell step quiets the immune/inflammatory load — it's how you lower the histamine and cytokine spill so the patient can actually tolerate binders and antifungals without flaring. The core moves: H1 + H2 blockers as the floor, a natural stabilizer layer (quercetin/luteolin, DAO before meals, Perimine — a Nathan favorite — and PEA for the neural-inflammation piece), escalating to cromolyn or ketotifen when that isn't enough. Full agents and exact doses are in the MCAS stabilization protocol below — this is the same "reduce inflammation" step, just named where it belongs in the sequence.
Limbic retraining — program selection
| Patient | Program |
|---|---|
| Bedridden / very low energy | Gupta (Amygdala Retraining) — listen-only, 5/10/15-min options; "almost anyone can do 5 minutes" |
| More OCD flavor | DNRS (Annie Hopper) — spoken rounds with gestures/movement |
| Wants comprehensive + vagal integration | Primal Trust (Cathleen King) — has a 5-min/day, 40-day track |
| Christian-belief, wary of "New-Agey" content | Brain Rewire (Brooklyn Hanna) |
| Too compromised for any structured program | Start with EMDR and/or osteopathic cranial (mostly vagal) — then add a limbic piece |
| Children | DNRS from age 7 if a parent does the cues; most programs at 10+ |
Vagal work
Exam pearls: have the patient repeat "Aah" and watch the uvula (should bounce; barely moving = vagal issue); ask them to gag — many sensitive patients can't. The vagus is ~80% sensory.
Menu: cues of safety (your voice, room, manner) → Safe & Sound Protocol → Rosenberg exercises → osteopathic cranial → FSM → Brain Tap → EFT/EMDR.
- Rosenberg Basic Exercise: lie back, hands behind head, move eyes fully to one side 20–30 sec until a yawn/sigh; stop if nothing happens.
Vagal devices — dose them down for sensitive patients
Neck (GammaCore) and ear (TruVaga) units are too much for most sensitives — use the wrist Apollo Neuro, and ignore the manufacturer's 3-hour instruction. Start 3–5 minutes once daily, increase slowly to 10–15 min, intensity set so they barely feel it (apps: Calm, Unwind).
Daily vagal toning — home practices
Cheap, self-administered, and cumulative — have the patient pick 2–3 and do them daily:
- Extended exhale — make the out-breath longer than the in-breath (e.g., in 4 / out 6–8) for a few minutes; the exhale is the parasympathetic lever.
- Hum / gargle / "Voooo" / chant "Om" — vibrates the vagus through the larynx.
- Cold to the face — a cold splash or cool pack over the eyes/cheeks triggers the dive reflex and shifts to parasympathetic.
- Lie on the right side, gentle joint rotations, and a weighted blanket (~10% of body weight) for calming pressure.
- Ear tVNS — a transcutaneous vagus ear-clip at the concha ("Point Zero"), used gently and briefly.
- Support tone with omega-3s and choline (alpha-GPC / CDP-choline).
Trauma-Release Exercises (TRE) — for the stuck, guarded patient
Bercelli/Levine method: a short sequence of leg/psoas-fatigue positions ending with the knees drawn gently together until a spontaneous neurogenic tremor releases through the legs and pelvis — the body discharging held survival tension. The patient stays in control: straighten the legs and the shaking stops. Start with only a minute or two, and go slowly in sensitive or highly traumatized patients (it can be activating). Best learned from a certified provider before home practice.
MCAS — full stabilization protocol dosing
MCAS is a clinical diagnosis (blood/urine mediator tests are notoriously unreliable — most need a cold centrifuge; biopsy needs CD117 staining). The tell is a reaction within 10–15 minutes of eating that fluctuates day to day. If the MCAS component is real, you often see noticeable improvement within 2 weeks. And it is curable — because we find and treat the trigger (mold, Lyme, Bartonella, COVID, EMF).
Empiric starting regimen
| Agent | Dose | Role |
|---|---|---|
| Quercetin | 250–500 mg, 30 min before each meal + at bedtime (work up) | Mast-cell stabilizer. ~20% can't tolerate (COMT SNP / GI). |
| Loratadine (Claritin) | 10 mg at bedtime | H1 blocker |
| Famotidine (Pepcid) | 20 mg at bedtime | H2 blocker |
Start H1/H2 once daily; many need them 2–3× daily for full effect. If one H1 is only partially helping, swap to another before escalating:
- H1 options: loratadine (Claritin) 10 mg, fexofenadine (Allegra) 180 mg, cetirizine (Zyrtec) 10 mg, levocetirizine (Xyzal) 5 mg — each once daily, may go to BID; for breakthrough, hydroxyzine (Atarax) 10–25 mg hs/PRN or diphenhydramine (Benadryl) 25–50 mg PRN.
- H2 options: famotidine (Pepcid) 20–40 mg BID, cimetidine (Tagamet) 200–400 mg BID, nizatidine (Axid) 150 mg BID.
Trial a low-histamine diet for 2 weeks — about half improve (continue); half don't (don't stay strict).
Natural adjuncts (all 30 min before meals unless noted)
- NeuroProtek LP (quercetin+luteolin, low-dose 40 mg — good for kids / the quercetin-intolerant): start 500 mg once daily → 1–2 caps
- DAO enzymes before each meal · AllQlear (tryptase inhibitor) 1–2 chewables before meals · Perimine (perilla) 1 tab 1–2×/day
- PEA (Mirica or Vitalitus) — stabilizer + reduces neural inflammation — work up to 2 po TID
Pharmaceutical stabilizers
- Ketotifen (a favorite — leukotriene inhibitor + stabilizer + H1). Normal start 1 mg hs then before each meal. sensitive start 0.1–0.25 mg (rarely 0.05 mg); compounded.
- Cromolyn sodium — 100 mg vials; very sensitive patients open a vial and take 1–2 drops before meals, work up. (Oral Gastrocrom is the pharmaceutical form.)
- Montelukast (Singulair) 10 mg daily (evening) — a leukotriene-receptor antagonist; the accessible first step for leukotriene-driven symptoms (wheeze, congestion, post-nasal drip, GI), often tried before Zileuton. Watch the FDA neuropsychiatric boxed warning — counsel on mood changes.
- Zileuton (Zyflo) 600 mg BID — a leukotriene-synthesis (5-LOX) inhibitor for refractory, leukotriene-driven mast-cell symptoms; a more expensive option often used after resistance/tolerance to cromolyn; monitor LFTs.
- GLP-1 receptor-agonist microdosing (emerging) — e.g. tirzepatide ~0.5 mg SubQ weekly. Mast cells carry GLP-1/GIP receptors, and low-dose agonism reduces degranulation and NF-κB signaling; used as an adjunct in a treatment-resistant MCAS case once standard stabilizers plateaued. Off-label; start low, monitor GI tolerance.
Probiotics — choose by histamine effect
B. infantis, longum, bifidum, breve; L. gasseri, rhamnosus, plantarum
L. casei, brevis, reuteri, bulgaricus (common in yogurt/blends)
See the interactive MCAS Ladder in Tools.
Special sensitivities that masquerade as the "sensitive patient"
When a patient reacts to nearly everything, screen for these distinct, treatable overlays before assuming it's purely limbic/mast-cell. Each has its own fix.
- Oxalate overload — lower high-oxalate foods very slowly (a fast drop triggers "oxalate dumping" and a flare); support with calcium/magnesium citrate, and go easy on vitamin C (it converts to oxalate).
- Salicylate intolerance — reduce the salicylate load (aspirin, Pepto-Bismol, and high-salicylate botanicals like quercetin, resveratrol, curcumin, CBD, plus high-sal foods) and support the detox pathways that clear them (glucuronidation, sulfation, glycine conjugation).
- Thiamine (B1) deficiency and EMF reactivity — both are on Nathan's "sensitive-patient impediment" list; correct thiamine, and measure/shield/avoid EMF (Cornet meter) in the patient who flares near electronics.
- Carbon-monoxide exposure / secondary porphyria — chronic low-level CO needs oxygen (sometimes months); a secondary porphyria picture responds to IV 10% dextrose (D10) given when symptoms are worst.
Low-dose ketamine & LDI — for the patient who can't tolerate any treatment Beyond the guide
Low-dose ketamine IV can get the truly untreatable patient over the threshold to start — begin 5–10 mg in the super-sensitive (usual ~25 mg), especially where anxiety is the barrier. LDI (Low Dose Immunotherapy) is the other key tool for immune over-reactivity — see the sequencing pearls for how the faculty dosed it in their cases.
Why sub-anesthetic ketamine helps the sensitized / MCAS patient — and how small the dose is
The therapeutic dose is a fraction of the anesthetic dose. Anesthetic induction is ~1–2 mg/kg IV (≈70–140 mg for a 70-kg adult); the doses below are roughly 0.1–0.5 mg/kg — about a quarter to a tenth of that — which is why the patient stays awake and the effect is neuro-modulatory rather than sedating.
The mechanism that matters here is central sensitization. Ketamine is an NMDA-receptor antagonist, and NMDA-driven "wind-up" is the amplifier behind the sensitized state — the same over-tuned nervous system that produces multi-sensory, food, chemical, EMF, and drug reactivity, refractory migraine, and nociplastic pain. Blocking NMDA turns down that gain (strong evidence in fibromyalgia and central-sensitization pain syndromes). Ketamine is also anti-neuroinflammatory — in models it quiets microglial activation and lowers TNF-α, IL-6, and IL-1β — and in-vitro work on IV anesthetics suggests ketamine can inhibit mast-cell degranulation rather than trigger it (it is not a clinically significant histamine-releaser at these doses). So for MCAS/sensitivity the rationale is: reset central sensitization + calm neuroinflammation (and possibly stabilize mast cells) to get a hypervigilant patient over the threshold where the rest of the protocol becomes tolerable.
Be honest about the evidence tier: there is no RCT of ketamine for MCAS itself. The support is strongest for depression/anxiety, refractory migraine, and central-sensitization pain; using it in the sensitized/mast-cell patient is a reasoned extrapolation from the shared central-sensitization + neuroinflammation mechanism, best used as a threshold/adjunct tool, not a first-line MCAS drug.
| Indication | Typical sub-anesthetic IV dosing |
|---|---|
| Sensitized "can't tolerate anything" patient (Nathan) | Flat micro-dose: 5–10 mg (super-sensitive) → ~25 mg usual; go low, especially if anxiety is the barrier |
| Depression / anxiety / mood | 0.5 mg/kg over 40 min; series of ~6 infusions over 2–3 wk (dose-ranging found 0.5 mg/kg the sweet spot) |
| Central sensitization / fibromyalgia / nociplastic pain | 0.3–0.5 mg/kg over 10–30 min; higher continuous protocols exist for refractory pain |
| Refractory / non-resolving migraine & headache | Start 0.25–0.35 mg/kg, 60–90 min infusions, escalate over ~4 days (some centers to >2 mg/kg); ~85% respond, ⅓ hold ≥3 mo. Intranasal used for home "booster." |
| Addiction / substance-use disorder | 0.5–0.71 mg/kg paired with psychotherapy (KAP), in a structured program |
Safety & scope: a Schedule-III controlled substance — give in a monitored setting (BP, HR, dissociation), watch for transient hypertension/tachycardia and psychomimetic effects (usually resolve ~30 min), screen for psychosis/uncontrolled hypertension, and mind abuse/diversion potential and urinary effects with chronic use. Rare true IgE hypersensitivity to ketamine exists — not a reason to avoid it, but document consent. Prescribe within your licensure/scope; pair with the limbic-vagal work, don't substitute for it. (NMDA/central-sensitization: Ochsner J 2021 fibromyalgia review; Practical Neurology 2024 migraine; neuroinflammation: Lu, Fundam Clin Pharmacol 2020 & Pharmaceuticals 2025; mast cell: Anesth Analg 2005 IV-anesthetic mast-cell study; psychiatric dosing: BJPsych Open 2021 systematic review.)
Sublingual (oral) low-dose ketamine — an at-home titration
When IV isn't practical, a sublingual route lets the sensitive patient self-titrate slowly. Pre-load antioxidant support first (start these before ketamine): MSM 1,000 mg/day, NAC 1,000 mg/day, curcumin 500–1,000 mg/day, magnesium bisglycinate ~250 mg nightly, all with food.
Titration: troches — start ~25 mg; if no benefit after 2 weeks, increase 25 mg every 5 days until benefit or "activation" (restlessness, racing thoughts, insomnia) appears — then drop to the last tolerated dose. Or with 50 mg/mL liquid, 2 drops under the tongue at bedtime, hold 5 min before swallowing, advance by 2 drops nightly. Most find it sedating (take at night); ~30% find it activating (take AM). No driving for 60 min after. Typical ceiling ~175 mg/day. Back off for restlessness, insomnia, headache, dizziness, or irritability. Controlled substance — prescribe and monitor within your scope; combine with the limbic/vagal work, not instead of it.
Teaching cases
Worked complex cases showing the reasoning, the fold-elevation lab reads, and the actual sequence used. Full visit-by-visit detail expands in the next build from the case decks.
Sarah — 17 F · PANS / Lyme / mold / Alpha-Gal / seizures
Neuroimmune presentation with OCD, tics, dysautonomia, dermatographism. Mold panel positive (ochratoxin, gliotoxin, trichothecenes) — read on a factorial basis (~6× / ~9× / ~2×). Vector-borne markers positive. Sequenced: stabilize mast cells → limbic/vagal → drainage → antimicrobial (bioflavonoids → PC → binders → antifungals) → mito last.
Maggie — 38 F · Tourette's / MCAS / TBRF / Hashimoto's
Thyroid panel: TSH 4.8, Free T3 low, TPO 480 — active Hashimoto's atop the neuroimmune picture. Illustrates reading autoantibody magnitude and layering hormone support into the reboot phase.
Interactive tools
🧭 Mold Treatment Matcher antifungal + protocol
Click the testing that came back — nasal culture (fungal & bacterial), OAT, stool PCR / GI-MAP, urine mycotoxins (RealTime · Mosaic · Vibrant), environmental / ERMI — and it aggregates everything into one plan: antifungal coverage & matrix, sinus & gut ladders with S/CS dosing, binders matched to the toxins, Herx management, copy-ready prescriptions with pharmacy contacts, recovery peptides, and trough monitoring. A live safety screen removes agents contraindicated for the patient, and the immune-state selector drives the thymic-peptide choice.
🔎 Marker lookup — significance & connections
Type any marker (lab, OAT organic acid, cytokine, ratio, or mycotoxin) to see what it means at a glance and what to read alongside it. Search by name, alias, or keyword (e.g. "candida", "kidney", "MCAS").
Functional Lab Interpreter dual-method
Enter whatever labs you have. It flags each value against the functional-optimal target (not just the conventional range), computes every ratio it can, reads the iron quadrant and thyroid pattern, and flags the missing standing-order labs. Blanks are fine — it uses what you give it.
Lab fold-elevation calculator signature
Enter each result and the lab's reference cutoff → see how many times above normal it is, ranked. This is the comparing-and-ratio read to interpret and to show the patient.
Mycotoxin → binder & detox lookup
Adult binder titration helper
Pediatric / weight-based dose calculator
MCAS stabilization ladder
Work down the ladder, holding at the step that controls symptoms.
Mold symptom questionnaire
A comprehensive multi-system symptom screener with a weighted exposure history — check what applies to get a likelihood read and a system-by-system picture. A screening aid, not a diagnosis.
Combined kit order builder Alight toxin kits
Check the patient's positive mycotoxins and get one consolidated product list — every formula from the matching Alight kits, merged and de-duplicated — so you order once instead of stacking overlapping bundles and ending up with a shelf of extra bottles.
This is an optional convenience for clinicians who use Crista's Alight line — a simplicity path, not a requirement. The full, brand-independent treatment options (Dr. Nathan's approach, generic binders/antifungals/agents) live in the treatment sections and the Mycotoxin Library — use whichever products you prefer.
Evidence & key literature
For anyone who wants the peer-reviewed footing — this is a newer field for most clinicians: a curated core of the mold/mycotoxin literature, grouped by claim. Not exhaustive — a defensible starting library you can share with a colleague or lean on yourself. (Compiled largely from J. Mather, MD's mold literature review, Sept 2025, plus the faculty decks.)
Symptoms & neuro-cognitive effects of mold exposure
- Empting L. Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure. Toxicol Ind Health. 2009;25(9-10):577-82.
- Kilburn KH. Neurobehavioral and pulmonary impairment in 105 adults with indoor mold exposure… Toxicol Ind Health. 2009;25(9-10):681-92.
- Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clin Ther. 2018;40(6):903-17. (PMID 29880330)
- Bredesen DE. Inhalational Alzheimer's disease: an unrecognized — and treatable — epidemic. Aging (Albany NY). 2016;8(2):304-13. (PMID 26870879)
New-onset autoimmunity after water-damaged-building exposure
- Campbell AW, Thrasher JD, et al. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds… Arch Environ Health. 2003;58(8):464-74.
- Pathak S, et al. Innate immune recognition of molds and homology to the inner-ear protein cochlin in autoimmune inner-ear disease. J Clin Immunol. 2013;33(7):1204-15.
- Lieberman A, Curtis L, Campbell A. New-onset CIDP following exposure to a water-damaged home with high airborne mold. J Neurol Res. 2017.
Mold/mycotoxin biomarkers & antibodies after exposure
- Vojdani A, Campbell AW, et al. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in a water-damaged building. Arch Environ Health. 2003;58(6):324-36.
- Hooper DG, et al. Mycotoxin detection in human samples from patients exposed to environmental molds. Int J Mol Sci. 2009;10(4):1465-75. (urinary validation)
- Shaw W, Pratt-Hyatt M. Biochemical markers in the urine associated with GI mold-overgrowth linked with elevated urinary mycotoxins. Townsend Letter #436, 2019.
- Vidal A, et al. Mycotoxin Biomarkers of Exposure: A Comprehensive Review. Compr Rev Food Sci Food Saf. 2018.
Mycotoxins are airborne, enter the body, and associate with disease
- Brasel TL, et al. Detection of airborne Stachybotrys chartarum macrocyclic trichothecene mycotoxins in the indoor environment. Appl Environ Microbiol. 2005;71(11):7376-88.
- Brasel TL, et al. Detection of trichothecene mycotoxins in sera from individuals exposed to Stachybotrys… Arch Environ Health. 2004;59(6):317-23.
- Wu TY, et al. Prevalence of Aspergillus-derived mycotoxins (ochratoxin, aflatoxin, gliotoxin) in ME/CFS urinalysis. Int J Environ Res Public Health. 2022;19(4):2052.
- Brewer JH, Thrasher JD, et al. Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins. 2013;5(4):605-17. · …is naso-sinus fungal biofilm the culprit? Toxins. 2013;6(1):66-80.
- Arce-López B, et al. Biomonitoring of Mycotoxins in Plasma of Patients with Alzheimer's and Parkinson's Disease. Toxins. 2021;13:477.
Carcinogenicity, pregnancy & child development
- Magnussen A, Parsi MA. Aflatoxins, hepatocellular carcinoma and public health. World J Gastroenterol. 2013;19(10):1508-12.
- Shuaib FM, et al. Association between birth outcomes and aflatoxin B1 biomarker blood levels in pregnant women. Trop Med Int Health. 2010;15(2):160-7.
- Kadan G, Aral N. Effects of Mycotoxins on Child Development. Curr Mol Pharmacol. 2021;14(5):770-81.
Treatment evidence
- Brewer JH, Hooper D, Muralidhar S. Intranasal antifungal therapy in patients with chronic illness associated with mold and mycotoxins. Glob J Med Res. 2015;15(K2):29-33. · Intranasal nystatin therapy… 15(K5):33-36.
- Campbell AW, Anyanwu EC, Vojdani A. High-dose IVIG + itraconazole in chronic mycotic demyelinating optic neuritis. ScientificWorldJournal. 2003;3:640-6.
- Pollock BH, et al. Intervention trial with calcium montmorillonite clay in an aflatoxin-exposed population. Food Addit Contam. 2016;33(8):1346-54. (binder evidence)
- Castro-Marrero J, et al. CoQ10 + NADH in ME/CFS: randomized, double-blind, placebo-controlled. Nutrients. 2021;13(8):2658. (mitochondrial support)
Faculty, sources & disclaimer
With gratitude to my teachers & sources
This guide synthesizes what I have learned over years of mentorship and clinical practice. It draws on the teaching of many clinicians and researchers, and the guidance in the tool is written as clinical guidance rather than as a running citation — because so often these teachers converge on the same approach, and no single line belongs to any one of them. With gratitude to all of them:
- Mold, mycotoxin & CIRS: Neil Nathan, MD; Ritchie C. Shoemaker, MD (biotoxin pathway, VCS, symptom-cluster analysis, HLA); Jill Crista, ND; Marie Matheson, ND; Joseph Brewer, MD (mycotoxin/CFS research); Michael Ruscio, DC.
- Environmental & toxicant medicine: Walter Crinnion, ND & Joseph Pizzorno, ND (Clinical Environmental Medicine); Lyn Patrick, ND and EMEI Global; the AAEM / NAEM and ISEAI communities; Richard Semelka, MD (gadolinium).
- Tick-borne & coinfection: Richard Horowitz, MD (MSIDS); Robert Mozayeni, MD; the ILADS community.
- Functional / neuroendocrine & peptides: the A4M faculty and James LaValle; Ruth Kriz, APRN (hypercoagulation); Bruce Patterson, MD / IncellDx (Long-COVID); Vladimir Khavinson (bioregulators); Dale Bredesen, MD (ReCODE).
- Limbic, vagal & MCAS: Annie Hopper (DNRS); Ashok Gupta; Cathleen King, DPT (Primal Trust); Carolyn McMakin, DC (FSM); and the broader mast-cell and functional/regenerative-medicine community.
Named instruments, protocols and products referenced in the tool (the biotoxin pathway, ERMI/HERTSMI-2, the Cell Danger Response, symptom-cluster questionnaires, and brand or compounded formulations) belong to their originators.
